Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of biotech company 10x Genomics (NASDAQ:TXG ... Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed ...

Get access to 10+ additional ProTips and comprehensive valuation metrics with InvestingPro's detailed research report. In other recent news, 10X Genomics announced preliminary fourth-quarter sales ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT ... Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (LSE ... of all funds dedicated to 0A88 is 0.10%, an increase of 21.48%. Total shares owned ...

Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq ... 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m. Eastern Time. Interested parties may access a live webcast ...